Actively Recruiting

Age: 18Years +
All Genders
ID06894602

Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis

Led by University Hospital, Brest · Updated on 2026-03-20

100

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the link between ultrasound-detected lesions in temporal and axillary arteries and relapse in patients with giant cell arteritis, a disease affecting medium and large blood vessels. This prospective, bicentric longitudinal observational study aims to understand how ultrasound abnormalities relate to disease relapse and clinical outcomes, using the OGUS score as a predictive tool. The study involves patients routinely monitored for giant cell arteritis who receive temporal artery ultrasound as part of their standard care. There are no additional interventions or treatments, as this is a non-interventional study. Participants will undergo three visits including clinical, biological, and ultrasound assessments over the course of their routine follow-up. Participants will have clinical examinations, blood tests including C-Reactive Protein and Sedimentation Rate, and ultrasound imaging at baseline, 6 months, and 12 months. Researchers will track relapse based on EULAR 2018 criteria at 6 and 12 months, along with various clinical and biological markers. The study includes no extra costs or constraints and aims to follow patients for up to 12 months after enrollment.

CONDITIONS

Brief Title

Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years or older
  • Diagnosis of giant cell arteritis meeting ACR 2022 criteria
  • No opposition expressed to participate
Not Eligible

You will not qualify if you...

  • Unable to understand the study protocol or under guardianship or curatorship
  • Not affiliated with the French Social Security system

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 12 months

Participants who undergo routine care are observed with clinical, biological, and ultrasound examinations as part of their disease follow-up.

3 visits including clinical, biological, and ultrasound examinations

Trial Site Locations

Total: 2 locations

1

Chu Brest

Brest, France, 29200

Actively Recruiting

2

Ch Quimper

Quimper, France, 29107

Actively Recruiting

Loading map...

Research Team

S

Sandrine Pr JOUSSE-JOULIN

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Cross-over, Randomized, Open-label, Single-centre, Phase II ...

Giant Cell Arteritis

Actively Recruiting

1 location

Randomized Double-Blind Placebo-Controlled Trial of Abatacep...

Giant Cell Arteritis

Actively Recruiting

9 locations

Armenian Nationwide Registry of Systemic Autoimmune and Auto...

Behcet Disease

Actively Recruiting

6 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here